Table 2.
Compound | Authors | Target | Chemical class | Lowest IC50 (strain) |
---|---|---|---|---|
6 |
Sperandeo and Brun [[66]] |
- |
Pyrazolylnaphthoquinones, 5-aminoisoxazole |
0.11 μg/mL (K1) |
7 |
Silva et al. [67] |
- |
1,4-naphthoquinones |
0.03 μM (FcB1) |
8 |
Charris et al. [68] |
β-haematin |
Thieno(2,3-b)quinoline |
74.42%1 |
9 |
Cunico et al. [69] |
Aspartyl protease |
Hydroxyethylpiperazines |
4.6 μM (3D7) |
10 |
Cunico et al. [70] |
Aspartyl protease |
Hydroxyethyylpiperazines |
5.1 μg/mL (W2) |
11 |
Gnoatto et al. [71] |
β-haematin |
Piperazine, 3-acetylursolic acid |
0.08 μM (FcB1) |
12 |
de Sá et al. [72] |
|
Betulinic acid |
5.99 μM (W2) |
13 |
Pinheiro et al. [73] |
- |
Sesquiterpenes |
0.05 ng/mL (P. falciparum mefloquine resistant) |
14 |
Barbosa et al. [74] |
- |
Ozonides |
13.6 μg/mL |
15 |
Oliveira et al. [75] |
Cysteine proteases |
Semicarbazone, Thiosemicarbazone |
7.2 μM (W2) |
16 |
Camacho et al. [76] |
β-haematin |
Benzimidazole-5-carbohydrazides |
8.43 μM |
17 |
Corrales et al. [77] |
Hypoxanthine-guanine phosphoribosyltransferase |
6-thiopurine Steroids |
82%1 |
18 |
Barazarte et al. [78] |
β-haematin |
Pyrazolo and pyrimido benzothiazine dioxide |
92.32%2 |
19 |
Barazarte et al. [79] |
β-haematin |
Benzothiazines |
78.17%2 |
20 |
Vellasco Junior et al. [80] |
Aspartyl protease |
Thioetherhydroxyethyl, Sulfonamides |
15 μM (W2) |
21 |
Dominguez et al. [81] |
β-haematin |
Chlorovinyl sulfones |
0.025 μM (W2) |
22 |
Dominguez et al. [82] |
β-haematin |
Sulfonamide chalcones |
0.48 μM (W2) |
23 |
León et al. [83] |
Glucose metabolism β-haematin |
Sulfonylureas |
1.2 μM (W2) |
24 |
Arancibia et al. [84] |
β-haematin |
Rhenium bioorganometalics, Aminoquinoline |
0.048 μM (3D7) |
25 |
Rojas Ruiz et al. [85] |
β-haematin |
Aminoquinolines, thiazolidinone |
0.25 μM (3D7) |
26 |
Charris et al. [86] |
β-haematin |
E-2-quinolinylbenzo-cycloalcanones |
90%3 |
27 |
Vashist et al. [87] |
β-haematin |
Quinolone, 6-thiopurine |
inactive |
28 |
de Souza et al. [88] |
β-haematin |
4-aminoquinolines, platinum (II) complexes |
84 %4 |
29 |
Cunico et al. [89] |
β-haematin |
4-aminoquinolines |
1.39 μg/mL (W2) |
30 |
Rodrigues et al. [90] |
β-haematin |
Quinoline |
Active |
31 |
Domínguez et al. [91] |
Cysteine protease falcipain |
Quinolinyl chalcones |
19 μM (FcB1) |
32 |
Ferrer et al. [92] |
β-haematin |
Chloroquinolines |
94.93%3 |
33 |
Navarro et al. [93] |
β-haematin |
Gold-chloroquine complexes |
−5 |
34 |
Domínguez et al. [94] |
Cysteine protease β-haematin |
Phenylurenyl chalcones |
1.76 μM |
35 |
de Andrade-Neto et al. [95] |
- |
Naphthoquinones, Phenazines |
1.67 μM (W2) |
36 |
Hilário et al. [96] |
- |
3-alkylpyridines alkaloids |
<3.38 μM (W2) |
37 | Rodrigues et al. [97] | β-haematin | Bisquinoline | 56.76 %2 |
1 Percentage of inhibition of parasite growth (P. berghei in mice) at day 9 (dose: 10 mg/kg).
2 Inhibition of globin proteolysis (IGP) expressed as percentage.
3 Inhibition of β-haematin synthesis (IβHS) expressed as percentage.
4 Inhibition of parasite multiplication on days (dose: 25 mg/kg).
5 Activity expressed as IC50(CQDP)/IC50(complex).